Non-Cystic Fibrosis Bronchiectasis (NCFB) Market

Aug 11, 2020

10 likes | 109 Views

The prevalence of Non-cystic Fibrosis Bronchiectasis in the 7MM was 772,285 in 2017. The prevalence of NCFB in the United States was found to be 443,632 in 2017, while Germany has around 45,560 prevalent cases. The market size of Non-cystic Fibrosis Bronchiectasis in the 7MM was found to be USD 1,211 Million in 2017, according to DelveInsight, NCFB market in the 7MM is expected to change in the study period 2017u20132030. Increase in research activities, increasing disease prevalence, surge in a number of clinical studies are some of the key market drivers for the Non-cystic Fibrosis Bronchiectasis market. The key pharma players in the Non-cystic Fibrosis Bronchiectasis market include Aradigm , Zambon, Insmed, Novartis and many others. For more details on Non-Cystic Fibrosis Bronchiectasis (NCFB) Market visit: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-market

DelveInsight

Download Presentation

Non-Cystic Fibrosis Bronchiectasis (NCFB) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D